Viridian TherapeuticsVRDN
NASDAQPharmaceuticals
No cached AI snapshot yet for VRDN.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
252 employees103.07M shares outstandinglisted 2014-06-18
Next earnings ~May 5, 2026
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Latest News
Showing market-wide stock news
Bitcoin retreats after crypto bill setback, Fed next
This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
Gold outlook hinges on Fed signals; metal could test $4,200: Kotak Sec
US Dollar: Higher yields and oil support – MUFG
Bond Investors Are on Edge. Here's Why Stock Investors Should Pay Attention.
Wall St futures edge higher in countdown to Fed decision
Related Stocksin Pharmaceuticals
Ready to see the live AI view on VRDN?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing VRDN side-by-side with live signals.